AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36198565 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36198701 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive spinal neuromodulation during activity-based neurorehabilitation therapy (ABNT), 2x/week for 8 weeks
Number of subjects: 16
Study 36198701 — intervention group
Group type: COMPARATOR
Intervention: Activity-based neurorehabilitation therapy (ABNT) alone
Number of subjects: 16
Study 36198701 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety endpoint
Number of subjects: 16
Study 36199536 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lower mediastinal lymphadenectomy along with total or proximal gastrectomy
Number of subjects: 1036
Study 36199536 — intervention group
Group type: COMPARATOR
Intervention: Open lower mediastinal lymphadenectomy along with total or proximal gastrectomy
Number of subjects: 1036
Study 36200380 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline treatment for Hodgkin lymphoma
Number of subjects: 0
Study 36200417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucidinostat 40 mg twice per week (BIW)
Number of subjects: 55
Study 36200421 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (150x10^6 CAR T cells)
Number of subjects: 20
Study 36200421 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (450x10^6 CAR T cells)
Number of subjects: 20
Study 36200421 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (800x10^6 CAR T cells)
Number of subjects: 20
Study 36200421 — intervention group
Group type: EXPERIMENTAL
Intervention: HBI0101 (all cohorts)
Number of subjects: 20
Study 36200629 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal dynamics of serum levels of Glial Fibrillary Acidic Protein (GFAP)
Number of subjects: 0
Study 36200668 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab monotherapy
Number of subjects: 0
Study 36200701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir treatment
Number of subjects: 15
Study 36200701 — intervention group
Group type: COMPARATOR
Intervention: Acute Omicron infection (control group)
Number of subjects: 15
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: High disease activity
Number of subjects: 1915
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with glucocorticoids
Number of subjects: 1915
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with rituximab
Number of subjects: 1915
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: Public health insurance
Number of subjects: 1915
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestizos ethnicity
Number of subjects: 1915
Study 36201124 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male gender, higher disease activity, presence of comorbidities
Number of subjects: 1915
Study 36201124 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 1915
Study 36201124 — intervention group
Group type: COMPARATOR
Intervention: ICU admission
Number of subjects: 1915
Study 36201124 — intervention group
Group type: COMPARATOR
Intervention: Death due to COVID-19
Number of subjects: 1915
Study 36201124 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive mechanical ventilation (NIMV) or high flow oxygen devices
Number of subjects: 1915
Study 36201124 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 1915
Study 36201226 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal access to PrEP offered to adolescents and adults at elevated risk during population-level HIV testing
Number of subjects: 0
Study 36201380 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing telephone intervention
Number of subjects: 58
Study 36201380 — intervention group
Group type: COMPARATOR
Intervention: Physical activity education control
Number of subjects: 58
Study 36201392 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) system
Number of subjects: 17
Study 36201392 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 17
Study 36201545 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 40981
Study 36201545 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim without sulfamethoxazole
Number of subjects: 40981
Study 36201545 — intervention group
Group type: COMPARATOR
Intervention: Fluoroquinolones and other antibiotics (post-hoc analysis excluding ophthalmic drops)
Number of subjects: 40981
Study 36201545 — intervention group
Group type: COMPARATOR
Intervention: Oral Fluoroquinolones
Number of subjects: 40981
Study 36201564 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative care practices (ICPs)
Number of subjects: 89
Study 36201564 — intervention group
Group type: COMPARATOR
Intervention: Children from migrant families
Number of subjects: 89
Study 36202450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage (IPH)
Number of subjects: 244
Study 36202450 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque volume
Number of subjects: 244
Study 36202450 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of IPH and total plaque volume to the ECST risk score
Number of subjects: 244
Study 36202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in perivascular adipose tissue (PVAT) density
Number of subjects: 474
Study 36202455 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque volume (PV)
Number of subjects: 474
Study 36202455 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAT density
Number of subjects: 474
Study 36202537 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic screening
Number of subjects: 0
Study 36202561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioband Tricuspid Valve Reconstruction System
Number of subjects: 37
Study 36202825 — intervention group
Group type: EXPERIMENTAL
Intervention: ChARMin assessments (active and passive Range of Motion, Strength, Resistance to Passive Movement, Quality of Movement, Circle, and Workspace)
Number of subjects: 30
Study 36202865 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the radial and median nerves using epineural electrodes
Number of subjects: 2
Study 36202865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive interface controlled by voluntary actions
Number of subjects: 2
Study 36202997 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211 50-µg booster dose
Number of subjects: 895
Study 36202997 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273.211 100-µg booster dose
Number of subjects: 895
Study 36202997 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273 50-µg booster dose
Number of subjects: 895
Study 36203049 — intervention group
Group type: EXPERIMENTAL
Intervention: prehospital thrombolysis
Number of subjects: 146
Study 36203049 — intervention group
Group type: EXPERIMENTAL
Intervention: in-hospital thrombolysis
Number of subjects: 146
Study 36203049 — intervention group
Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary intervention (pPCI)
Number of subjects: 146
Study 36203049 — intervention group
Group type: COMPARATOR
Intervention: overall performance
Number of subjects: 146
Study 36203049 — intervention group
Group type: COMPARATOR
Intervention: system improvements
Number of subjects: 146
Study 36203163 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative comorbidity measures based on the 5-year history of number of hospital admissions, length of stay, and time since latest admission in 36 comorbidity categories
Number of subjects: 188965
Study 36203163 — intervention group
Group type: COMPARATOR
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 188965
Study 36203163 — intervention group
Group type: COMPARATOR
Intervention: Simplified Acute Physiology Score (SAPS3)
Number of subjects: 188965
Study 36203163 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative comorbidity measures
Number of subjects: 188965
Study 36203210 — intervention group
Group type: COMPARATOR
Intervention: Deep-hypo
Number of subjects: 64
Study 36203210 — intervention group
Group type: COMPARATOR
Intervention: Mild-hypo
Number of subjects: 64
Study 36203544 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg, maximum dose 1000 mg) plus standard of care (SOC)
Number of subjects: 1019
Study 36203544 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 1019
Study 36203563 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (0.3ml intramuscular, homologous)
Number of subjects: 39
Study 36203563 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (0.5ml intramuscular, homologous)
Number of subjects: 39
Study 36203563 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac (0.5ml intradermal)
Number of subjects: 39
Study 36203563 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (2 doses intramuscular, 1 dose intradermal)
Number of subjects: 39
Study 36203760 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable sauna bath (30-min, 45°C sauna bath, daily for 10 days)
Number of subjects: 51
Study 36203760 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable sauna bath
Number of subjects: 51
Study 36203789 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustocerebrography (ACG) system
Number of subjects: 20
Study 36203789 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study 36203789 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustocerebrography (ACG) data
Number of subjects: 20
Study 36203975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 mg/kg r-tPA
Number of subjects: 2666
Study 36203975 — intervention group
Group type: COMPARATOR
Intervention: 0.90 mg/kg r-tPA
Number of subjects: 2666
Study 36203998 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 310
Study 36203998 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 310
Study 36204243 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 8 mg once daily
Number of subjects: 240
Study 36204243 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat 15 mg once daily
Number of subjects: 240
Study 36204243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 36204243 — intervention group
Group type: EXPERIMENTAL
Intervention: Venglustat (preferred dose based on stage 1 safety data)
Number of subjects: 240
Study 36204554 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensory prosthesis (Walkasins)
Number of subjects: 44
Study 36204759 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with cognitive training (OS)
Number of subjects: 30
Study 36204759 — intervention group
Group type: EXPERIMENTAL
Intervention: Board game training (BG)
Number of subjects: 30
Study 36204759 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 30
Study 36204779 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp supervision for lay leaders
Number of subjects: 9
Study 36204820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) at a targeted dose of 0.75 × 10^6 CAR T cells/kg
Number of subjects: 97
Study 36205071 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV Vaccinations at Acute Visits
Number of subjects: 0
Study 36205071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent Adolescent Preventive Visits
Number of subjects: 0
Study 36205505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myelofibrosis (MF)
Number of subjects: 0
Study 36205505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with essential thrombocythemia (ET)
Number of subjects: 0
Study 36205505 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with MF or ET
Number of subjects: 0
Study 36205505 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall symptom burden in MF and ET cohorts
Number of subjects: 0
Study 36205505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower risk MF and low- or high-risk ET
Number of subjects: 0
Study 36205514 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT02 administered subcutaneously via autoinjector (AI), 40 mg, for 8 weeks
Number of subjects: 0
Study 36205514 — intervention group
Group type: EXPERIMENTAL
Intervention: AVT02 administered via prefilled syringe in the extension phase
Number of subjects: 0
Study 36205563 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 0
Study 36205910 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 4695
Study 36205910 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 4695
Study 36205910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study 36205913 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Posture Index (FPI-6)
Number of subjects: 38
Study 36205913 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Posture Rating (NYPR)
Number of subjects: 38
Study 36206041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemigatinib, 13.5 mg orally once daily for 14 consecutive days, followed by 7 days off therapy
Number of subjects: 107
Study 36206189 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH therapy (8 Gy in a single fraction delivered at ≥40 Gy per second)
Number of subjects: 10
Study 36206189 — intervention group
Group type: EXPERIMENTAL
Intervention: FLASH therapy
Number of subjects: 10
Study 36206298 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy
Number of subjects: 13
Study 36206609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 526
Study 36207039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyotube Stain 468
Number of subjects: 103
Study 36207039 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-developed liquid reagent cocktail
Number of subjects: 103
Study 36207229 — intervention group
Group type: EXPERIMENTAL
Intervention: Allostatic load measurement
Number of subjects: 0
Study 36207366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie meal test
Number of subjects: 101
Study 36207609 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PtCT) in gBRCA1/2m carriers (N=300)
Number of subjects: 1222
Study 36207609 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2m carriers (N=300)
Number of subjects: 1222
Study 36207609 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy (PtCT) in gBRCA1/2wt patients (N=922)
Number of subjects: 1222
Study 36207609 — intervention group
Group type: COMPARATOR
Intervention: Non-platinum-based chemotherapy (non-PtCT) in gBRCA1/2wt patients (N=922)
Number of subjects: 1222
Study 36207706 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program implemented in DMCCs
Number of subjects: 29191
Study 36207737 — intervention group
Group type: EXPERIMENTAL
Intervention: In-ICU red blood cells transfusion
Number of subjects: 1551
Study 36208004 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vitiligo
Number of subjects: 142
Study 36208017 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB-100 with nab-paclitaxel (Arm A)
Number of subjects: 40
Study 36208017 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB-100 (Arm B)
Number of subjects: 40
Study 36208712 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release superficial to the transverse carpal ligament (ERSTCL)
Number of subjects: 100
Study 36208712 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional Chow endoscopic release)
Number of subjects: 100
Study 36208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 67
Study 36209063 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirm Rx™ ICM in supine posture
Number of subjects: 99
Study 36209063 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirm Rx™ ICM in parasternally oriented position (n=44)
Number of subjects: 99
Study 36209063 — intervention group
Group type: COMPARATOR
Intervention: Confirm Rx™ ICM in 45°-relative-to-sternum orientation (n=46)
Number of subjects: 99
Study 36209118 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 4055
Study 36209118 — intervention group
Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 4055
Study 36209118 — intervention group
Group type: EXPERIMENTAL
Intervention: Study medication (all types)
Number of subjects: 4055
Study 36209118 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment guidelines adherence
Number of subjects: 4055
Study 36209149 — intervention group
Group type: EXPERIMENTAL
Intervention: eReferral to state tobacco quitlines
Number of subjects: 11
Study 36209149 — intervention group
Group type: EXPERIMENTAL
Intervention: eReferral implementation strategies
Number of subjects: 11
Study 36209149 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff survey
Number of subjects: 11
Study 36209432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymph drainage (MLD)
Number of subjects: 194
Study 36209432 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional manual lymph drainage (MLD)
Number of subjects: 194
Study 36209432 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo manual lymph drainage (MLD)
Number of subjects: 194
Study 36209432 — intervention group
Group type: COMPARATOR
Intervention: Decongestive lymphatic therapy (DLT)
Number of subjects: 194
Study 36209441 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200 mg
Number of subjects: 1755
Study 36209441 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100 mg
Number of subjects: 1755
Study 36209441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1755
Study 36209441 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1755
Study 36209441 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1755
Study 36209795 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related functional connectivity in language processing
Number of subjects: 150
Study 36210252 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruism-tailored educational intervention (spoken and written communication) highlighting altruistic benefits of accepting the seasonal influenza vaccine.
Number of subjects: 73
Study 36210252 — intervention group
Group type: EXPERIMENTAL
Intervention: Altruism-tailored communication approach
Number of subjects: 73
Study 36210299 — intervention group
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA 1000 mg IV administered every 2 weeks, extending to 3 weeks starting from cycle 7
Number of subjects: 14
Study 36210362 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blockade followed by curative surgery
Number of subjects: 35
Study 36210362 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blockade
Number of subjects: 35
Study 36210362 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative surgery
Number of subjects: 35
Study 36210430 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported high levels of mental distress
Number of subjects: 553
Study 36210430 — intervention group
Group type: COMPARATOR
Intervention: Self-reported low levels of mental distress
Number of subjects: 553
Study 36210430 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of mental distress (regardless of diagnosis)
Number of subjects: 553
Study 36210430 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of mental distress
Number of subjects: 553
Study 36210430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with one or more psychological diagnosis
Number of subjects: 553
Study 36210430 — intervention group
Group type: EXPERIMENTAL
Intervention: High CORE-10 score and high number of consultations
Number of subjects: 553
Study 36210483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36210487 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg IV every 2 weeks while remaining on the same NHTs (abiraterone acetate or enzalutamide)
Number of subjects: 8
Study 36210487 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 8
Study 36210799 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0
Study 36210799 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36211411 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum IgG and breast milk IgG and IgA antibody titres
Number of subjects: 85
Study 36211411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera IgG titres at 7-months of age
Number of subjects: 85
Study 36211411 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarities between maternal and cord IgG titres
Number of subjects: 85
Study 36211530 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided, web-based positive affect regulation skills (PARK) delivered over 6 weeks.
Number of subjects: 0
Study 36211552 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (3 months)
Number of subjects: 89
Study 36211552 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant trastuzumab without exercise (Control Group - CG)
Number of subjects: 89
Study 36211588 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (alirocumab)
Number of subjects: 160
Study 36211588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 36211703 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinosaur Augmented Reality photo-taking (2018)
Number of subjects: 1915
Study 36211703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-and-Stand fitness challenge (2019)
Number of subjects: 1915
Study 36211795 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme (care as usual plus guided self-help stress management and cognitive behavioural intervention)
Number of subjects: 212
Study 36211795 — intervention group
Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 212
Study 36211795 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care programme
Number of subjects: 212
Study 36211944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum drinking of a cool sport drink (237 mL every 15-20 min)
Number of subjects: 0